Stephan Mathas
YOU?
Author Swipe
View article: Recombination junctions from antibody isotype switching classify immune and DNA repair dysfunction
Recombination junctions from antibody isotype switching classify immune and DNA repair dysfunction Open
Personalized assessment of immunocompetence and DNA double-strand break (DSB) repair requires methods that are sensitive to genetic and molecular complexity beyond the well-known monogenic disorders. Inspired by decades of research using B…
View article: Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial Open
Takeda Oncology.
View article: Comparative <scp>DNA</scp> Methylation Profiling of Human and Murine <scp>ALK</scp>‐Positive B‐Cell Neoplasms
Comparative <span>DNA</span> Methylation Profiling of Human and Murine <span>ALK</span>‐Positive B‐Cell Neoplasms Open
Structural genomic variants leading to anaplastic lymphoma kinase (ALK) gene fusions and aberrant expression of the ALK tyrosine kinase are the hallmark of subtypes of T‐ and B‐lineage neoplasms, namely ALK‐positive anaplastic large lympho…
View article: Preclinical <i>in vitro</i> and <i>in vivo</i> evidence for targeting CD74 as an effective treatment strategy for cutaneous T-cell lymphomas
Preclinical <i>in vitro</i> and <i>in vivo</i> evidence for targeting CD74 as an effective treatment strategy for cutaneous T-cell lymphomas Open
Background Prognosis and quality of life in patients with advanced cutaneous T-cell lymphoma (CTCL), particularly in those with Sézary syndrome (SS) or advanced-stage mycosis fungoides (MF), are poor. Monoclonal antibodies or antibody–drug…
View article: Targeted Treatment Additions Ibrutinib + Bortezomib + R-CHOP for Higher-Risk DLBCL: Efficacy, Feasibility and Molecular Signatures for Future Treatment Decisions
Targeted Treatment Additions Ibrutinib + Bortezomib + R-CHOP for Higher-Risk DLBCL: Efficacy, Feasibility and Molecular Signatures for Future Treatment Decisions Open
Introduction Targeted treatment additions to R-CHOP for patients with diffuse large B-cell lymphoma (DLBCL) did fail to improve outcome in recent phase III trials. However, there are molecular subgroups that benefit, in retrospect. We have…
View article: High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial Open
Else Kröner-Fresenius Foundation, Riemser Pharma, and Medical Center-University of Freiburg.
View article: JUN mediates senescence and immune cell recruitment to prevent prostate cancer progression
JUN mediates senescence and immune cell recruitment to prevent prostate cancer progression Open
Background Prostate cancer develops through malignant transformation of the prostate epithelium in a stepwise, mutation-driven process. Although activator protein-1 transcription factors such as JUN have been implicated as potential oncoge…
View article: Transcriptional reprogramming by mutated IRF4 in lymphoma
Transcriptional reprogramming by mutated IRF4 in lymphoma Open
Disease-causing mutations in genes encoding transcription factors (TFs) can affect TF interactions with their cognate DNA-binding motifs. Whether and how TF mutations impact upon the binding to TF composite elements (CE) and the interactio…
View article: Impact of PET‐2 guided treatment de‐escalation on time‐to‐recovery from cancer‐related fatigue in advanced stage Hodgkin Lymphoma: results from the GHSG HD18 study
Impact of PET‐2 guided treatment de‐escalation on time‐to‐recovery from cancer‐related fatigue in advanced stage Hodgkin Lymphoma: results from the GHSG HD18 study Open
Introduction: Persisting cancer related fatigue (CRF) has impact on health related quality of life (HRQoL) and social re-integration of patients with Hodgkin lymphoma (HL). The GHSG HD18 trial established treatment PET-2 guided de-escalati…
View article: Toxicities at one year follow‐up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study Group
Toxicities at one year follow‐up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study Group Open
Introduction: The HD21 trial compares BrECADD with eBEACOPP for the first-line treatment of advanced stage classical Hodgkin Lymphoma (AS-cHL). We previously reported a superior acute tolerability profile for BrECADD. However, persisting t…
View article: Ibrutinib + bortezomib + R‐CHOP for higher‐risk DLBCL: Feasibility, efficacy and molecular predictors
Ibrutinib + bortezomib + R‐CHOP for higher‐risk DLBCL: Feasibility, efficacy and molecular predictors Open
Introduction: Most recent phase III trials investigating single targeted treatment additions to R-CHOP in patients with diffuse large B-cell lymphoma (DLBCL) failed, at least in part, due to the high heterogeneity of this disease. While re…
View article: Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors
Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors Open
BACKGROUNDAdoptive transfer of EBV-specific T cells can restore specific immunity in immunocompromised patients with EBV-associated complications.METHODSWe provide results of a personalized T cell manufacturing program evaluating donor, pa…
View article: Mouse models of human multiple myeloma subgroups
Mouse models of human multiple myeloma subgroups Open
Multiple myeloma (MM), a tumor of germinal center (GC)-experienced plasma cells, comprises distinct genetic subgroups, such as the t(11;14)/CCND1 and the t(4;14)/MMSET subtype. We have generated genetically defined, subgroup-specific MM mo…
View article: A multimorphic mutation in IRF4 causes human autosomal dominant combined immunodeficiency
A multimorphic mutation in IRF4 causes human autosomal dominant combined immunodeficiency Open
Interferon regulatory factor 4 (IRF4) is a transcription factor (TF) and key regulator of immune cell development and function. We report a recurrent heterozygous mutation in IRF4, p.T95R, causing an autosomal dominant combined immunodefic…
View article: A new type of transcriptional reprogramming by an IRF4 mutation in lymphoma
A new type of transcriptional reprogramming by an IRF4 mutation in lymphoma Open
SUMMARY PARAGRAPH Disease-causing mutations in genes encoding transcription factors (TFs) are a recurrent finding in hematopoietic malignancies and might involve key regulators of lineage adherence and cellular differentiation 1–3 . Such m…
View article: Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group Open
Introduction: PET-guided treatment of newly diagnosed advanced stage (AS) classical Hodgkin Lymphoma (cHL) patients with eBEACOPP (escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procar-bazine, predniso…
View article: PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma
PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma Open
Background Anaplastic large cell lymphoma (ALCL) is an aggressive non-Hodgkin T cell lymphoma commonly driven by NPM-ALK. AP-1 transcription factors, cJUN and JUNb, act as downstream effectors of NPM-ALK and transcriptionally regulate PDGF…
View article: S203: ABSCOPAL EFFECT OF RADIOTHERAPY AND NIVOLUMAB IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: PRE-PLANNED INTERIM ANALYSIS OF THE INTERNATIONAL GHSG PHASE II AERN TRIAL
S203: ABSCOPAL EFFECT OF RADIOTHERAPY AND NIVOLUMAB IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: PRE-PLANNED INTERIM ANALYSIS OF THE INTERNATIONAL GHSG PHASE II AERN TRIAL Open
Background: Failure of anti-PD1 checkpoint blockade in relapsed or refractory Hodgkin lymphoma (r/r HL) constitutes an unmet medical need. It has been postulated that anti-PD1 and localized radiotherapy (RT) may work synergistically to ind…
View article: Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase KDM4C in B-cell lymphomas
Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase KDM4C in B-cell lymphomas Open
Histone methylation-modifiers, such as EZH2 and KMT2D, are recurrently altered in B-cell lymphomas. To comprehensively describe the landscape of alterations affecting genes encoding histone methylation-modifiers in lymphomagenesis we inves…
View article: Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma
Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma Open
Purpose Evidence on the effect of self-protection via social distancing and wearing face-masks on infections during chemotherapy is currently not available. We asked if the occurrence of acute infections during chemotherapy for advanced-st…
View article: Aberrant Expression of and Cell Death Induction by Engagement of the MHC-II Chaperone CD74 in Anaplastic Large Cell Lymphoma (ALCL)
Aberrant Expression of and Cell Death Induction by Engagement of the MHC-II Chaperone CD74 in Anaplastic Large Cell Lymphoma (ALCL) Open
In 50–60% of cases, systemic anaplastic large cell lymphoma (ALCL) is characterized by the t(2;5)(p23;q35) or one of its variants, considered to be causative for anaplastic lymphoma kinase (ALK)-positive (ALK+) ALCL. Key pathogenic events …